MedPath

Progesterone

Generic Name
Progesterone
Brand Names
Bijuva, Crinone, Endometrin, Prochieve, Prometrium
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
57-83-0
Unique Ingredient Identifier
4G7DS2Q64Y
Background

Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization , as well as in other formulations to promote and support pregnancy. Please see Medroxyprogesterone acetate, Megestrol acetate, Dydrogesterone and Hydroxyprogesterone entries for information on various other forms of progesterone.

Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin . Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes .

Indication

Gelatinized capsules

The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea .

Vaginal gel

Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .

Vaginal insert

This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women .

Injection (intramuscular)

This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer .

Tablets, contraceptive

The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy .

Associated Conditions
Abnormal Uterine Bleeding, Amenorrhea, Endometrial hyperplasia caused by conjugated estrogen, Moderate to Severe Vasomotor Symptoms, Pregnancy, Secondary Amenorrhea, Recurrent spontaneous preterm birth
Associated Therapies
Assisted Reproductive Technology therapy

Efficacy of Micronized Natural Progesterone Vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.

Phase 4
Recruiting
Conditions
IVF
Interventions
First Posted Date
2023-07-20
Last Posted Date
2025-01-17
Lead Sponsor
Instituto Bernabeu
Target Recruit Count
150
Registration Number
NCT05954962
Locations
🇪🇸

Instituto Bernabeu, Elche, Alicante, Spain

Rhythmic Estradiol and Bone Health

Phase 4
Completed
Conditions
Osteoporosis Risk
Menopause
Interventions
First Posted Date
2023-06-15
Last Posted Date
2025-02-05
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
48
Registration Number
NCT05903820
Locations
🇳🇱

Amsterdam UMC, Amsterdam, Netherlands

Progesterone Primed Ovarian Stimulation Protocol Versus Antagonist Protocol for PCO Patient

Not Applicable
Not yet recruiting
Conditions
Infertility
Polycystic Ovary Syndrome
IVF
Interventions
Drug: conventional antagonist protocol
First Posted Date
2023-05-06
Last Posted Date
2023-05-06
Lead Sponsor
Fayoum University
Target Recruit Count
210
Registration Number
NCT05847660

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

Not Applicable
Recruiting
Conditions
Luteal Phase Support
Interventions
First Posted Date
2023-05-01
Last Posted Date
2023-05-01
Lead Sponsor
Shaare Zedek Medical Center
Target Recruit Count
144
Registration Number
NCT05838105
Locations
🇮🇱

Shaare Zedek medical center, Jerusalem, Israel

Prolonged Progesterone to Prevent Preterm Birth From IVF - ET

Phase 4
Not yet recruiting
Conditions
Preterm Birth
Interventions
First Posted Date
2023-03-28
Last Posted Date
2023-03-28
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
100
Registration Number
NCT05787509

Estrogen Supplementation and Bone Health in Women With CF

Phase 4
Recruiting
Conditions
Cystic Fibrosis
Hypoestrogenism
Interventions
Drug: Transdermal estrogen
First Posted Date
2023-01-30
Last Posted Date
2024-11-11
Lead Sponsor
Johns Hopkins University
Target Recruit Count
75
Registration Number
NCT05704036
Locations
🇺🇸

Johns Hopkins, Baltimore, Maryland, United States

Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy

First Posted Date
2022-10-19
Last Posted Date
2024-06-04
Lead Sponsor
Angelica Lindén Hirschberg
Target Recruit Count
520
Registration Number
NCT05586724
Locations
🇸🇪

Karolinska University Hospital, Stockholm, Sweden

Rescue Progesterone Supplementation During Frozen Embryo Transfer

Phase 2
Active, not recruiting
Conditions
Fertility Issues
Embryo Implantation
Frozen Embryo Transfer
Interventions
First Posted Date
2022-09-26
Last Posted Date
2024-01-16
Lead Sponsor
Clinique Ovo
Target Recruit Count
150
Registration Number
NCT05555121
Locations
🇨🇦

Clinique Ovo, Montreal, Quebec, Canada

GnRH Agonist for Luteal Phase Support.

Not Applicable
Conditions
Use of GnRH Agonist Alone for Luteal Phase Support in Fresh IVF Cycles
Interventions
First Posted Date
2022-08-02
Last Posted Date
2022-08-02
Lead Sponsor
Shaare Zedek Medical Center
Target Recruit Count
150
Registration Number
NCT05484193
Locations
🇮🇱

Shaare Zedek medical Center, Jerusalem, Israel

Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle.

Recruiting
Conditions
Infertility, Female
Interventions
First Posted Date
2022-07-25
Last Posted Date
2025-02-21
Lead Sponsor
ART Fertility Clinics LLC
Target Recruit Count
40
Registration Number
NCT05473273
Locations
🇦🇪

ART Fertility Clinics LLC, Abu Dhabi, United Arab Emirates

© Copyright 2025. All Rights Reserved by MedPath